Clinical Trial Update: Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of Ropeginterferon alfa-2b for treating myelodysplastic/myeloproliferative neoplasm overlap syndromes and c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Chronic Myeloid Leukemia
• Myelodysplastic Myeloproliferative Neoplasm
• Myelodysplastic Myeloproliferative Neoplasm Not Otherwise Specified
• Myelodysplastic Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis
• Myelomonocytic Leukemia

Drugs mentioned

• Ropeginterferon alfa-2b (ropeginterferon alfa-2b)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Status: NOT_YET_RECRUITING